Clinical Trial: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)
Brief Summary:
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment.
PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.
Detailed Summary:
OBJECTIVES:
- To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).
- To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.
OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.
Sponsor: Children's Oncology Group
Current Primary Outcome:
- Expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in ALCL
- Correlation of CD4, FOXP3, and CD276 with ALK autoantibody response in patients enrolled in ANHL0131
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Children's Oncology Group
Dates:
Date Received: June 2, 2011
Date Started: May 2011
Date Completion:
Last Updated: May 17, 2016
Last Verified: May 2016
